ORGO
Organogenesis Holdings Inc
NASDAQ · Biotechnology
$3.77
+0.06 (+1.62%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 464.61M | 460.10M | 178.18M | 163.70M | 183.70M |
| Net Income | 824.9K | 735.2K | 16.02M | 15.03M | 18.71M |
| EPS | — | — | — | — | — |
| Profit Margin | 0.2% | 0.2% | 9.0% | 9.2% | 10.2% |
| Rev Growth | +1.0% | +1.0% | +15.4% | +17.3% | -10.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 1.17M | 1.17M | 25.76M | 23.91M | 23.00M |
| Total Equity | 238.06M | 238.06M | 159.67M | 148.92M | 172.86M |
| D/E Ratio | 0.00 | 0.00 | 0.16 | 0.16 | 0.13 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 11.92M | 11.21M | 21.94M | 20.76M | 25.89M |
| Free Cash Flow | — | — | 12.41M | 17.26M | 13.87M |